A Phase 2 interventional study of OTL38 for Injection and Near infrared camera imaging system in Lung Neoplasms and Lung Cancer, sponsored by On Target Laboratories, LLC. Completed at 6 sites in 2 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-03-24.
Sponsored by On Target Laboratories, LLC · Phase 2, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,460 studies in Lung Neoplasms with a site in United States — 422 open to participants now, 643 under way, 52 of them phase 3. Lung Neoplasms · United States.
Among the 2,460 studies in Lung Neoplasms with a site in United States, this one is the 565th largest by enrollment of the 1,906 interventional ones that give a count, is one of 89 that started in 2017, is one of 633 in phase 2, and was the 1,355th registered.
5,427 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.
Browse Lung Neoplasms studies →422 of the 2,460 studies in Lung Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+
University of Chicago · Sites in United States
Ages 18+
Fred Hutchinson Cancer Center · Sites in United States
Ages 50–77 · Healthy volunteers
Fred Hutchinson Cancer Center · Sites in United States
Ages 50–80 · Healthy volunteers
Roswell Park Cancer Institute · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 995 Lung Neoplasms studies recruiting now, 684 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,460 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 659 · Phase 2 866 · Phase 3 179 · Phase 4 21
First in 1990; this study’s year is marked. 89 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is above the median of 60 across 3,660 interventional studies indexed under Lung Neoplasms.
Median enrollment 48 across the 1,906 interventional studies, 123 across the 442 observational. Of the 1,674 that completed or were terminated, 582 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
619 of 2,460 have an industry lead sponsor. The 10 most frequent:
On Target Laboratories, LLC is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
On Target Laboratories, LLC has 3 studies filed under Lung Neoplasms — fewer than ten, so there is no comparison to draw.
243 of the studies in Lung Neoplasms with a site in United States that are under way reach primary completion within a year, 13 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07499674Phase 3Vergent Bioscience, Inc.Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung | 2026-12 |
| NCT06151574Phase 3Boehringer IngelheimBeamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment | 2026-12-10 |
| NCT03637816Phase 3M.D. Anderson Cancer CenterAnamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer | 2026-12-31 |
| NCT04093167Phase 3Canadian Cancer Trials GroupStudy of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer | 2026-12-31 |
| NCT03391869Phase 3M.D. Anderson Cancer CenterNivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer | 2027-03-31 |
Add all 243 to your calendar (.ics) → With an account.
Among the 2,460 studies in Lung Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase 2, multi-center, single dose, open-label, exploratory study in suspected lung cancer patients scheduled to undergo endoscopic or thoracic surgery per CT/positron emission tomography imaging based on standard of care. This study aims to assess the efficacy of OTL38 and Near Infrared Imaging (NIR) at identifying pulmonary nodules within the operating theater, and to assess the safety and tolerability of single intravenous doses of OTL38.
This is a phase 2, multi-center, single dose, open-label, exploratory study in suspected lung cancer patients scheduled to undergo endoscopic or thoracic surgery per CT/positron emission tomography (PET) imaging based on standard of care.
Two to three hours prior to surgery, patients will be infused with OTL38. After the patient is intubated and surgical site incised, the surgeon will locate and document all nodules identifiable by white light, manual palpation, and Near-Infrared Imaging (NIR). This will be documented and recorded. Surgery will be completed per surgeon's standard of care, afterwards the area will be reviewed under standard and infrared light. All samples will be sent for pathology and immunohistochemistry (IHC) evaluation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients in this arm will receive OTL38 for injection and undergo intraoperative imaging.
Drug: OTL38 for Injection · Device: Near infrared camera imaging system · Procedure: Endoscopic or Thoracic Surgery
Folate analog ligand conjugated with an indole cyanine-like green dye as a solution in vials containing 3 mL at 2 mg/mL
Also known as: OTL38
Near infrared camera imaging system
Endoscopic or Thoracic Surgery
Sensitivity or True Positive Rate (TPR)
Sensitivity or True Positive Rate (TPR) for OTL38 in combination with fluorescent light, defined as the proportion of fluorescent light positive tissue samples (nodule, synchronous lesion, and margin but excluding lymph nodes) that are histologically confirmed to be FR+ and lung cancer by central pathology relative to the total number of tissue samples confirmed to be FR+ and lung cancer by central pathology. Sensitivity = (True Positive)/(True Positive +False Negative)
Time frame: 1 day
False Positive Rate (FPR)
False positive rate (FPR) for OTL38 in combination with fluorescent light, for the purpose of this protocol, will be calculated as 1 - the Positive Predictive Value (PPV) and is defined as the proportion of fluorescent light positive tissue samples removed (nodule, synchronous lesion, and margin but excluding lymph nodes) that are histologically confirmed to be non-cancerous, or if cancerous, not FR+ and lung cancer, by central pathology relative to the total number of tissue samples removed with fluorescent light imaging. False Positive Rate = (False Positives) / (True Positives + False Positives)
Time frame: 1 day
Proportion of Patients With at Least 1 Clinically Significant Event (CSE)
Proportion of patients with at least 1 Clinically Significant Event (CSE as a result of utilizing OLT-38 and Near Infrared Imaging
Time frame: 1 day
Positive Margin Identification
Number of patients where at least one positive margin (fluorescent cancerous cells within 5 mm of the staple line) is identified with only OTL-38 and NIR
Time frame: 1 day
Synchronous Lesion Identification
Number of patients where at least one synchronous lesions is identified only with OTL-38 and NIR
Time frame: 1 day
Pulmonary Nodule Identification
Number of pulmonary nodules identified with OTL-38 and Near Infrared Imaging (NIR) that could not otherwise be identified by white light and palpation.
Time frame: 1 day
| Milestone | Patients Receiving OTL38 |
|---|---|
| Started | 100 |
| Completed | 97 |
| Not completed | 3 |
Sensitivity or True Positive Rate (TPR) for OTL38 in combination with fluorescent light, defined as the proportion of fluorescent light positive tissue samples (nodule, synchronous lesion, and margin but excluding lymph nodes) that are histologically confirmed to be FR+ and lung cancer by central pathology relative to the total number of tissue samples confirmed to be FR+ and lung cancer by central pathology. Sensitivity = (True Positive)/(True Positive +False Negative)
| proportion of lesions | Patients Receiving OTL38 |
|---|---|
| Sensitivity or True Positive Rate (TPR) | 0.854 (0.74 to 0.92) |
False positive rate (FPR) for OTL38 in combination with fluorescent light, for the purpose of this protocol, will be calculated as 1 - the Positive Predictive Value (PPV) and is defined as the proportion of fluorescent light positive tissue samples removed (nodule, synchronous lesion, and margin but excluding lymph nodes) that are histologically confirmed to be non-cancerous, or if cancerous, not FR+ and lung cancer, by central pathology relative to the total number of tissue samples removed with fluorescent light imaging. False Positive Rate = (False Positives) / (True Positives + False Positives)
| proportion of lesions | Patients Receiving OTL38 |
|---|---|
| False Positive Rate (FPR) | 0.138 (0.08 to 0.23) |
Proportion of patients with at least 1 Clinically Significant Event (CSE as a result of utilizing OLT-38 and Near Infrared Imaging
| proportion of participants | Patients Receiving OTL38 |
|---|---|
| Proportion of Patients With at Least 1 Clinically Significant Event (CSE) | 0.293 (0.194 to 0.410) |
Number of patients where at least one positive margin (fluorescent cancerous cells within 5 mm of the staple line) is identified with only OTL-38 and NIR
| Participants | Patients Receiving OTL38 |
|---|---|
| Positive Margin Identification | 8 |
Number of patients where at least one synchronous lesions is identified only with OTL-38 and NIR
| Participants | Patients Receiving OTL38 |
|---|---|
| Synchronous Lesion Identification | 7 |
Number of pulmonary nodules identified with OTL-38 and Near Infrared Imaging (NIR) that could not otherwise be identified by white light and palpation.
| number of pulmonary nodules | Patients Receiving OTL38 |
|---|---|
| Pulmonary Nodule Identification | 10 |
Collected over AEs were collected through Day 28 (+/- 4 days) from OTL38 administration. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Patients Receiving OTL38 | 0/100 (0%) | 14/100 (14%) | 94/100 (94%) |
| Event | Patients Receiving OTL38 |
|---|---|
| HaemothoraxRespiratory, thoracic and mediastinal disorders | 2/100 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 2/100 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 2/100 |
| PneumoniaInfections and infestations | 2/100 |
| ChylothoraxRespiratory, thoracic and mediastinal disorders | 1/100 |
| Lung disorderRespiratory, thoracic and mediastinal disorders | 1/100 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/100 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/100 |
| Hip fractureInjury, poisoning and procedural complications | 1/100 |
| Post procedural haemorrhageInjury, poisoning and procedural complications | 1/100 |
| Event | Patients Receiving OTL38 |
|---|---|
| Procedural painInjury, poisoning and procedural complications | 50/100 |
| NauseaGastrointestinal disorders | 33/100 |
| CoughRespiratory, thoracic and mediastinal disorders | 29/100 |
| Incision site painInjury, poisoning and procedural complications | 20/100 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 17/100 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 17/100 |
| VomitingGastrointestinal disorders | 17/100 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 13/100 |
| Chest painGeneral disorders | 12/100 |
| HypertensionVascular disorders | 11/100 |
| Age, Categorical(Participants) | Patients Receiving OTL38 |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 28 |
| >=65 years | 72 |
| Age, Continuous(years) | Patients Receiving OTL38 |
|---|---|
| Mean | 67.4 ± 9.35 |
| Sex: Female, Male(Participants) | Patients Receiving OTL38 |
|---|---|
| Female | 68 |
| Male | 32 |
| Ethnicity (NIH/OMB)(Participants) | Patients Receiving OTL38 |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 98 |
| Unknown or Not Reported | 1 |
| Race (NIH/OMB)(Participants) | Patients Receiving OTL38 |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 7 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 6 |
| White | 86 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Patients Receiving OTL38 |
|---|---|
| Netherlands | 10 |
| United States | 90 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2017 to primary completion in Oct 2018, 17 months.
Results were first posted in Mar 2023, 4 years 4 months after primary completion. A results delay was requested in Dec 2020.
Of 77 industry-sponsored phase 2 interventional studies under Lung Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 61. This study's 17 months is below that.
Counting every sponsor, half of 363 studies reached it within 65 months; a quarter within 34 and three quarters within 102.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pafolacianine
On Target Laboratories, LLC